Filgotinib hits more RA endpoints

Gilead and Galapagos took a step closer to submitting regulatory applications for filgotinib to treat rheumatoid arthritis after the partners reported positive data from the two remaining Phase III trials of the oral Janus kinase-1 (JAK-1) inhibitor.

On FINCH 1’s primary endpoint, once-daily 100 and 200 mg doses of filgotinib plus a stable dose of methotrexate both significantly improved ACR20 response rate at week 12 vs. placebo plus methotrexate (69.8% and 76.6%, respectively, vs. 49.9%, p<0.001 for both). The active control Humira adalimumab plus methotrexate led to an ACR20 response rate of 70.8%...